Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）

Inclusion Criteria: * Signed and dated informed consent * Age：18\~75 years; * Subjects with histologically or cytologically confirmed locally advanced and/or advanced NSCLC * at least two systematic chemotherapy with upwards of 1-line treatments or cannot suffer * The negative patients in EGFR\&ALK can participate or who positive in EGFR\&ALK, have or have not drug tolerance after the treatment with relative targeted drugs * Subjects with at least one measurable lesion as defined by RECIST (version 1.1) * Expected Survival Time: Over 3 months * ECOG PS：0-1, * main organs function is normal * The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it Exclusion Criteria: * 1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer) * lung squamous carcinoma * Other active malignancies requiring treatment * History of malignancy * Have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included * Abnormal coagulation (INR\>1.5 or PT\>ULN+4s or APTT \>1.5 ULN); Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation * take major surgical treatments or have serious trauma before grouping, or the impact of surgery or trauma has been eliminated for less than 14 days. * Patients with active or unable to control serious infections; * Patients with Grade II or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc male ≥ 450 ms, female ≥ 470 ms) ; Patients with grade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) \<50% (NYHA Classification) * Patients with non-healing wounds or fractures * with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus). * get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism * plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy * Patients with cirrhosis, decompensated liver disease, or active hepatitis Have suffered from hemorrhagic disease or coagulation dysfunction * diagnosed with disease which will severely endanger the security of patients or influence the completion of this research